Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer and various genetic conditions is an obvious home run. CRISPR Therapeutics ...
We asked 12 scientists, artists, and thought leaders to share how AI enabled them to create, explore, or understand something ...
8h
CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 10:45 AM ESTCompany ParticipantsSamarth Kulkarni - CEO ...
EDEN (short for environmentally-derived evolutionary network) processes evolutionary DNA from more than one million newly discovered species, collected over five years at 150 locations in 28 countries ...
Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually by 2050. Now, scientists at UC San Diego have unveiled a powerful new CRISPR ...
1d
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer Jennifer Doudna wants to build an entire ecosystem to bring these treatments ...
With this in mind, let's check out a blastoff-ready biotech stock you'll kick yourself for not buying in 2026. Image source: Getty Images.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results